美國

證券交易委員會 及交易所

華盛頓特區，20549

表格 6-K

依據法規13a-16或15d-16的相關規定，外國私人發行人的報告

依據1934年證券交易所法案所規定

2024年11月份

001-36345

(委員會 文件編號)

GALMED 藥品有限公司。

(依其章程所指定的註冊人姓名)

c/o Meitar Law Offices

16 Abba Hillel 白銀路

Ramat Gan, 5250608

(主要行政辦公室地址)

請用勾選來表示，是否該登記者提交或將提交覆蓋的年度報告

申報表20-F或40-F。

申報單 20-F ☒ 40-F ☐

On November 14, 2024, Galmed Pharmaceuticals Ltd. (the “Company”) entered into a Capital on Demand™ Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC, as sales agent (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, to or through the Sales Agent, ordinary shares, no par value per share (the “Ordinary Shares”), having an aggregate offering price of up to gross sale proceeds of up to $8,100,000.

Any sales of Ordinary Shares under the Sales Agreement will be made pursuant to a shelf registration statement on Form F-3 and the related prospectus (File No. 333-283241) (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “SEC”) on November 14, 2024, after such Registration Statement is declared effective by the Commission.

The Company is not obligated to sell any Ordinary Shares under the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, the Sales Agent will use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of The Nasdaq Stock Market LLC to sell Ordinary Shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. Upon delivery of a placement notice to the Sales Agent, and subject to the Company’s instructions in that notice, and the terms and conditions of the Sales Agreement generally, the Sales Agent may sell the Ordinary Shares by any method permitted by law deemed to be an “at the market offering” as defined by Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or through The Nasdaq Capital Market, or any other existing trading market for the Ordinary Shares, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or in any other method permitted by law.

根據銷售協議進行的發行將在以下情況之一提前終止: (a)根據協議所允許的情況下終止銷售協議，以及(b)雙方共識。銷售代理人根據銷售協議賣出普通股的義務需滿足特定條件和其他慣例的交割條件。公司將支付銷售代理人相當於根據銷售協議銷售普通股所得總收益的3.0%佣金，並同意向銷售代理人提供慣例的賠償和貢獻權。公司還同意就進入銷售協議而支付銷售代理人特定指明的費用。銷售協議含有慣例的陳述和保證，以及銷售根據該協議進行普通股的條件。

前述銷售協議的描述並非完整，並且完全受到對該協議全文的參考的限制，該協議的副本作為本報告六-K表的10.1展覽提交，並且透過此引用納入其中。

本六-K表報告不構成銷售的要約，也不構成購買的徵求 普通股 股份 此處討論的;亦不得在任何未在任何州或司法裁決下該省或司法裁決下的證券法之前註冊或取得資格為任何州或司法之內的典型股出售的要約、徵求或出售。

本六-K表已納入公司的S-8表註冊聲明(註冊號) 333-206292和 333-227441及公司的F-3表註冊聲明(註冊號) 333-272722且 333-283241).

展觀 指数

簽名

根據《證券交易法》的要求，報告申報人已授權其代表在此簽署該報告。